oncolytic virus

candle candles
Biotech

Candel glows with $100M RTW deal to fund cancer drug launch

As Candel gears up for a planned U.S. approval push for its prostate cancer drug, RTW has stepped in with $100 million to bankroll the launch.
James Waldron Feb 20, 2026 4:04am
Image of a neon sign with the word no lit up next to an unlit yes

Replimune's request for melanoma approval rejected by FDA

Jul 22, 2025 8:45am
U turn turn around refocus pivot street sign

Theriva prioritizes oncolytic adenovirus at expense of GvHD drug

Mar 7, 2025 4:47am
pass the torch deal sell buy acquisition

4 years on from launch, IconOVir sells oncolytic virus to UroGen

Feb 20, 2025 9:12am
Wall Street stock exchange finance shares share price Nasdaq

Candel burns bright as phase 3 cancer win sends stock up 200%

Dec 11, 2024 9:49am
Graphic showing arrows missing the bullseye on a target

Transgene's viral cancer vaccine flunks midphase test

Oct 14, 2024 4:59am